TRGNF News and Press, Transgene S.A. From 07/17/23

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese...

New immunological data assessed by tetramer staining confirms the induction of T cell responses in treated patients All trial patients treated with TG4050 monotherapy continue to remain in remission to date Transgene and NEC are preparing a Phase II trial to further demonstrate the potent...

TG4001 can induce de novo immune responses against HPV16 antigens E6 and E7 in patients with advanced HPV16-positive anogenital cancers Patients with complete objective response showed strong vaccine-induced immunoreactivity Transgene is preparing for a potentially registrational stud...

Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that desi...

Treatment of all Phase Ia cohorts in monotherapy completed with no safety concerns Stabilization of injected lesions in 11/18 patients An independent Safety Review Committee has approved initiation of the combination trial with pembrolizumab Regulatory News: Transgene (Euron...

Dr. Alessandro Riva, MD, appointed as the Company’s Chairman and CEO to accelerate the development of Transgene’s innovative immunotherapy portfolio New clinical data to be communicated in Q2 2023 on TG4001, TG4050 and BT-001 €17.0 million in cash and cash equivalents...

TG6050 is an oncolytic virus derived from Transgene’s Invir.IO® platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody, with the potential to trigger a powerful antitumor immune response. The Phase I Delivir trial will evaluate the intravenous (IV) administration of t...

Regulatory News: The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 5, 2023) at 9:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Il...

Current Chairman, Dr Alessandro Riva, MD, to become Chairman and Chief Executive Officer – Hedi Ben Brahim to retire as CEO. Decision made by AstraZeneca to terminate the oncolytic virus R&D collaboration. Transgene remains focused on its strategic priorities. Conference ca...

- New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation - In the head and neck cancer trial to date, all patients treated with TG4050 have remained disease-free...